Cost-utility analysis in depression: The McSad utility measure for depression health states

被引:36
|
作者
Bennett, KJ
Torrance, GW
Boyle, MH
Guscott, R
机构
[1] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada
[2] Univ Toronto, Dept Psychiat, Toronto, ON, Canada
[3] McMaster Univ, Ctr Hlth Econ & Policy Anal, Hamilton, ON L8S 4L8, Canada
[4] McMaster Univ, Sch Business, Hamilton, ON L8S 4L8, Canada
关键词
D O I
10.1176/appi.ps.51.9.1171
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Cost-utility analysis, used increasingly over the past decade to analyze costs and effects in treating physical diseases, has received little attention in psychiatry. This article briefly introduces the concepts and methods of utility measurement and illustrates it using depression as an example. The authors describe the McSad health state classification system for depression, a direct utility measure for depression, and report results of an application of McSad among 105 patients who had a recent history of depression. Utility measures express patient preferences for specific health states on a scale ranging from 0, representing death, to 1, representing perfect health. These scores provide the weights used to calculate the number of quality-adjusted Life-years gained by an intervention or set-vice. McSad allows a patient's depression health state to be classified according to level of functioning in six dimensions of depression and to be compared with other hypothetical depression health states in order to produce utility scores indicating the patient's relative preferences.
引用
收藏
页码:1171 / 1176
页数:6
相关论文
共 50 条
  • [1] Development and testing of a utility measure for major, unipolar depression (McSad)
    Bennett, KJ
    Torrance, GW
    Boyle, MH
    Guscott, R
    Moran, LA
    QUALITY OF LIFE RESEARCH, 2000, 9 (01) : 109 - 120
  • [2] Development and testing of a utility measure for major, unipolar depression (McSad)
    K.J. Bennett
    G.W. Torrance
    M.H. Boyle
    R. Guscott
    L.A. Moran
    Quality of Life Research, 2000, 9 : 109 - 120
  • [3] Cost-utility of tDCS in depression treatment
    Sauvaget, A.
    EUROPEAN PSYCHIATRY, 2023, 66 : S45 - S45
  • [4] COST-UTILITY ANALYSIS OF MAINTENANCE TREATMENT FOR RECURRENT DEPRESSION
    KAMLET, MS
    PAUL, N
    GREENHOUSE, J
    KUPFER, D
    FRANK, E
    WADE, M
    CONTROLLED CLINICAL TRIALS, 1995, 16 (01): : 17 - 40
  • [5] The cost-utility of screening for depression in primary care
    Valenstein, M
    Vijan, S
    Zeber, JE
    Boehm, K
    Buttar, A
    ANNALS OF INTERNAL MEDICINE, 2001, 134 (05) : 345 - 360
  • [6] Cost-utility analysis studies of depression management: A systematic review
    Pirraglia, PA
    Rosen, AB
    Hermann, RC
    Olchanski, NV
    Neumann, P
    AMERICAN JOURNAL OF PSYCHIATRY, 2004, 161 (12): : 2155 - 2162
  • [7] Pindolol augmentation of paroxetine and compliance in the treatment of depression: A cost-utility analysis
    Tome, M
    Isaac, M
    QUALITY OF LIFE RESEARCH, 1997, 6 (7-8) : 388 - 388
  • [8] Cost-utility of brief psychological treatment for depression and anxiety
    Hakkaart-van Roijen, L
    van Straten, A
    Rutten, MAF
    Donker, M
    BRITISH JOURNAL OF PSYCHIATRY, 2006, 188 : 323 - 329
  • [9] COST-UTILITY ANALYSIS OF VORTIOXETINE FOR THE TREATMENT OF MAJOR DEPRESSION DISORDERS IN CHINA
    Liu, M.
    Chen, W.
    VALUE IN HEALTH, 2019, 22 : S686 - S686
  • [10] Cost-Utility Analysis of Esketamine for Patients with Treatment-Resistant Depression in Italy
    Rognoni, Carla
    Falivena, Camilla
    Costa, Francesco
    Armeni, Patrizio
    PHARMACOECONOMICS, 2023, 41 (2) : 209 - 225